TScan Therapeutics Appoints Debora Barton, MD, as Chief

WALTHAM, Mass., July 07 28, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on developing T-cell therapies designed with T-cell receptors (TCRs) for the treatment of cancer patients, today announced the appointment of Debora Barton, MD, as Chief Medical Officer. Dr. Barton, a clinical oncologist experienced in the development of cellular therapies for cancer, brings to TScan nearly two decades of expertise in global clinical research and development, and executive leadership in large pharmaceutical companies and small and medium. biotechnology companies.

“We are delighted to welcome Debora to TScan at such a crucial time as we launch sites for our lead Phase 1 leukemia trial which is expected to begin enrolling patients mid-year,” said David. P. Southwell, President and Chief Executive Officer. . “Dr. Barton’s clinical experience in developing treatments for liquid and solid tumors comes at a good time for us as we advance our TCR program to the clinical stage in myeloid cancers and develop clinical programs for solid tumors. We look forward to working with her.

“I am delighted to join the TScan team at such an exciting time and look forward to bringing my expertise in clinical oncology and clinical research and development to support the progress of the company’s pipeline to develop TCRs. -T for the treatment of multiple tumor types,” said Dr. Barton. “The TScan team has rapidly advanced the science of the company in its efforts to provide effective new treatments for hematological malignancies and solid tumors. in the clinic, and I look forward to working with the team to bring TScan’s innovative therapies to the patients who need them.”

Prior to joining TScan, Dr. Barton was Chief Medical Officer at Carisma Therapeutics Inc., where she was responsible for clinical development, clinical operations, medical affairs and safety. Previously, Dr. Barton was Senior Vice President, Chief Clinical Officer and Chief Safety Officer at Iovance Biotherapeutics, Inc., where she oversaw several Phase 2 studies in solid tumors and led clinical efforts related to regulatory interactions. Prior to Iovance, Dr. Barton held positions of increasing responsibility in biotechnology and pharmaceutical companies, including Advanced Accelerator Applications SA, Celgene Corporation and Novartis. Dr. Barton is a board-certified clinical oncologist (MD) and board member of the American Cancer Society, the Tigerlily Foundation (Medical Advisory Board), a national breast cancer foundation that advocates and supports young women before, during and after the breast. cancer and Arovella Therapeutics Ltd (non-executive director). She holds a doctorate in medicine from the Pontificia Universidade Catolica Sao Paulo and completed her fellowship in oncology at the Federal University of Sao Paulo in Brazil.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR)-designed T-cell therapies (TCR-T) for the treatment of cancer patients. The Company’s lead TCR-T leukemia therapeutic candidates, TSC-100 and TSC-101, are being developed for the treatment of patients with hematological malignancies to eliminate residual leukemia and prevent relapse after a hematopoietic stem cell transplant. The Company is also developing multiplexed TCR-T therapeutic candidates for the treatment of various solid tumors. The Company has developed and continues to develop its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize various targets and are associated with multiple HLA types to provide personalized multiplexed TCR-T therapies to patients with various solid tumors.

Forward-looking statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the structure, timing and success of preclinical development and planned clinical trials. by the Company, and the potential benefits of any of the Company’s proprietary platforms or current or future product candidates in treating patients. TScan intends that these forward-looking statements be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify search statements by terms such as, but not limited to, “may”, “could”, “will”, “goal”, “intent”, “should”, “could”, “may”, “should”, “expect”, “believe”, “anticipate”, “project”, “target”, “design”, “estimate”, “predict”, “potential”, “plan”, “on the right path” or similar expressions or the negative of these terms. These forward-looking statements are based on current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The express or implied forward-looking statements included in this press release are only predictions and are subject es to a number of risks, uncertainties, and assumptions, including but not limited to: beneficial characteristics, safety, efficacy, therapeutic effects, and potential benefits of TCR- therapy candidates T; TScan’s expectation that its preclinical studies are predictive of clinical trial results; the timing of the initiation, progress and expected results of TScan’s preclinical studies, clinical trials and research and development programs; TScan’s plans for the development and commercialization of its TCR-T therapy candidates, if approved, including the sales strategy; estimates of the size of the addressable market for TScan’s TCR-T therapy candidates; TScan’s manufacturing capabilities and the scalable nature of its manufacturing process; TScan’s estimates of expenses, future milestone payments and revenues, capital requirements and additional funding requirements; TScan’s expectations regarding competition; TScan’s anticipated growth strategies; TScan’s ability to attract or retain key personnel; TScan’s ability to establish and maintain development partnerships and collaborations; TScan’s expectations regarding federal, state and foreign regulatory requirements; TScan’s ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScan’s existing capital resources to fund its future operating expenses and capital expenditure requirements; and the effect of the COVID-19 pandemic, including mitigation efforts and political, economic, legal and social effects, on any of the foregoing or other aspects of TScan’s business or operations; and other factors that are described in the “Risk Factors” and “Management‘s Discussion and Analysis of Financial Condition and Results of Operations” sections of TScan’s most recent Annual Report on Form 10-K and any other document that TScan has made or may make with the SEC in the future. All forward-looking statements contained in this release represent the views of TScan only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan expressly disclaims any obligation to update forward-looking statements.


Heather Savelle
TScan Therapeutics, Inc.
Vice President, Investor Relations
[email protected]

Joyce Allaire
LifeSci Advisors, LLC
General director
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8fe8de5c-f2c3-4e24-96b3-d7dc694c07ff

About Donnie R. Losey

Check Also

New rules loom as baseball pushes for better product in 2023

In other words, a lot of the game is spent waiting for something to happen …